How can food extracts consumed in the Mediterranean and East Asia suppress prostate cancer proliferation?

Mu Yao1, Chanlu Xie1, Maryrose Constantine1, Sheng Hua1, Brett D. Hambly2, Greg Jardine3, Paul Sved4 and Qihan Dong1,4,5*

1Department of Endocrinology, Central Clinical School and Bosch Institute, Room 394, Blackburn Building, D06, Royal Prince Alfred Hospital, The University of Sydney, Sydney, NSW 2006, Australia
2Department of Pathology, The University of Sydney, Sydney, NSW 2006, Australia
3Dr Red Nutraceuticals, Mt Nebo, QLD 4520, Australia
4Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
5School of Biomedical and Health Sciences, The University of Western Sydney, Sydney, Australia

(Submitted 7 January 2011 – Final revision received 16 September 2011 – Accepted 25 September 2011 – First published online 9 November 2011)

Abstract

We have developed a blend of food extracts commonly consumed in the Mediterranean and East Asia, named blueberry punch (BBP), with the ultimate aim to formulate a chemoprevention strategy to inhibit prostate cancer progression in men on active surveillance protocol. We demonstrated previously that BBP inhibited prostate cancer cell proliferation in vitro and in vivo. The purpose of this study was to determine the molecular mechanism responsible for the suppression of prostate cancer cell proliferation by BBP. Treatment of lymph node-metastasised prostate cancer cells (LNCaP) and bone-metastasised prostate cancer cells (PC-3 and MDA-PCa-2b) with BBP (up to 0.8%) for 72 h increased the percentage of cells at the G0/G1 phase and decreased those at the S and G2/M phases. The finding was supported by the reduction in the percentage of Ki-67-positive cells and of DNA synthesis measured by the incorporation of 5-ethynyl-2'-deoxyuridine. Concomitantly, BBP treatment decreased the protein levels of phosphorylated retinoblastoma, cyclin D1 and E, cyclin-dependent kinase (CDK) 4 and 2, and pre-replication complex (CDC6 and MCM7) in LNCaP and PC-3 cells, whereas CDK inhibitor p27 was elevated in these cell lines. In conclusion, BBP exerts its anti-proliferative effect on prostate cancer cells by modulating the expression and phosphorylation of multiple regulatory proteins essential for cell proliferation.

Key words: Proliferation: Cell cycle: Prostate cancer: Blueberry punch

Active surveillance, rather than immediate aggressive treatment, is emerging as a viable management option for men with prostate cancer. This strategy consists of close monitoring by prostate-specific antigen testing, physical examination, and periodic prostate biopsies aimed to identify the early signs of cancer progression. However, within the next 5 years, 30–40% of men under active surveillance will experience a rise in prostate-specific antigen or progress to high-grade disease, mandating radical surgery or radiotherapy. Thus, developing a chemoprevention strategy to inhibit cancer progression in these otherwise healthy men is of great importance and deserves urgent attention.

We envisage that food-based chemoprevention in combination with active surveillance could benefit these patients. The incidence of clinically important prostate cancer is lower in people living in the Mediterranean and Eastern Asia compared to Western societies. However, the incidence of occult prostate cancer was of little variation worldwide. It has been proposed that dietary factors are responsible for inhibiting or preventing the progression of occult to clinical prostate cancer. Thus, we have made a concerted effort to develop a blend of food extracts consumed in these regions, named blueberry punch (BBP). We reported recently that BBP reduced DNA synthesis as measured by thymidine incorporation and topoisomerase levels in prostate cancer cells in vitro and in vivo, respectively. In contrast, an equi-valent dose of BBP had little effect on non-cancerous prostate cells.

Abbreviations: BBP, blueberry punch; CDC6, cell division cycle 6; CDK, cyclin-dependent kinase; EdU, 5-ethynyl-2'-deoxyuridine; LNCaP, lymph node-metastasised prostate cancer cells; MDA-PCa-2b, bone metastasised androgen receptor positive prostate cells; PC-3, bone metastasised androgen receptor negative prostate cells; pRb, phospho-retinoblastoma.

*Corresponding author: Dr Q. Dong, fax +61 2 95161273, email qihan.dong@sydney.edu.au
phospholipase A2 by prostate cancer cells, as all three proteins were reduced after treatment with BBP. In mice, the growth of human prostate cancer cell xenograft was also inhibited with a dose of BBP (10% of drinking-water) that is applicable in humans. The aim of the present study was to determine the molecular mechanism responsible for the suppression of cell proliferation by BBP in human prostate cancer cell lines with different pathological attributes.

**Experimental methods**

**Blueberry punch preparation**

Fresh olive leaf, grape seed and skin, citrus skin (orange, mandarin, lemon, kaffir lime and Tahitian lime), green tea, turmeric and ginger were juiced individually in a fruit blender. The individual pulps were extracted with 60–95% ethanol in a ratio of 1:1 in weight for a minimum of 2 weeks. The ethanol-based extraction medium facilitates the extraction of both fat-soluble and water-soluble phytochemicals. A stainless-steel hydraulic press was used to separate the alcoholic extract from pulp. The resulting enriched extracts were blended and subjected to vacuum distillation to remove the alcohol and most of the water. The extracts were then added to blueberry fruit juice with a final concentration of 5%. BBP was manufactured by Dr Red Nutraceuticals Pty Limited (Mt Nebo, QLD, Australia). The major chemicals contained in BBP and their properties were described previously.

**Cell culture**

Lymph node-metastasised prostate cancer cells (LNCaP, CRL-1740, ATCC) and bone metastasised androgen receptor negative prostate cells (PC-3, CRL-1435, American Type Culture Collection, VA, USA) were grown in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% fetal calf serum (Hyclone), penicillin at 100 units/ml and streptomycin at 100 μg/ml. Bone metastasised androgen receptor positive prostate cells (MDA-PCa-2b, CRL-2422, ATCC) were grown in F-12K nutrient mixture (Invitrogen) supplemented with 20% fetal calf serum, penicillin at 100 units/ml, streptomycin at 100 μg/ml, epidermal growth factor (10 ng/ml), phosphoethanolamine, cholera toxin at 25 ng/ml, hydrocortisone at 0.1 ng/ml, 45 nM-selenious acid and insulin at 5 μg/ml, as previously described. All the cell lines were cultured at 37 °C in an incubator providing a humidified environment in the presence of 5% CO2 and 95% air.

**Treatment**

Exponentially growing cells were cultured in six-well plates. Exponentially growing cells were cultured in six-well plates, T25 flasks or T75 flasks for 3 days before treatment with BBP. BBP was first diluted to 0.8% in each culture medium and sterilised by filtration. Further dilutions were made in the corresponding medium to achieve lower concentrations in the untreated cells served as controls.

**Table 1.** Cell cycle phase distribution of lymph node-metastasised prostate cancer cells (LNCaP), bone metastasised androgen receptor negative prostate cells (PC-3) and bone metastasised androgen receptor positive prostate cells (MDA-PCa-2b) measured by flow cytometry

<table>
<thead>
<tr>
<th>Treatment</th>
<th>LNCaP</th>
<th>PC-3</th>
<th>MDA-PCa-2b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>G0/G1 phase</td>
<td>S phase</td>
<td>G2/M phase</td>
</tr>
<tr>
<td>0% BBP</td>
<td>73.1%</td>
<td>0.8%</td>
<td>12.3%</td>
</tr>
<tr>
<td>0.2% BBP</td>
<td>73.7%</td>
<td>0.6%</td>
<td>12.2%</td>
</tr>
<tr>
<td>0.4% BBP</td>
<td>79.6%</td>
<td>0.6%</td>
<td>14.8%</td>
</tr>
<tr>
<td>0.8% BBP</td>
<td>82.3%</td>
<td>0.6%</td>
<td>14.5%</td>
</tr>
</tbody>
</table>

BBP, blueberry punch.

*Mean values within a column with unlike superscript letters were significantly different (P<0.05).

**Average percentage of cells with standard deviation in three independent experiments.** Exponentially growing LNCaP, PC-3 or MDA-PCa-2b were treated with various doses of BBP for 72 h. The cells were collected, fixed, stained with propidium iodide and analysed by a flow cytometer.
Detection of cellular DNA synthesis

The cells were treated with BBP in T25 flasks and their DNA synthesis was monitored by the incorporation of 5-ethynyl-2’-deoxyuridine (EdU) to newly synthesised DNA with Click-It™ EdU Flow Cytometry Assay Kit (C35002; Invitrogen). Following this, 8 h before completion of treatment, the exhausted medium was removed and the cells were incubated in the fresh medium containing 10 μM-EdU and BBP at each corresponding concentration. The cells were then trypsinised and fixed in cold 70 % ethanol in PBS at 4°C overnight. The fixed cells were then washed with PBS containing 5 % fetal calf serum and the incorporated EdU was labelled with reaction cocktails according to the assay instructions. The labelled cells were analysed by a flow cytometer (BD FACSCalibur; BD Biosciences) equipped with CellQuest Pro software (BD Biosciences) to determine the percentage of cells with incorporated EdU.

Cell cycle analysis

The cell cycle distribution of the treated cells was determined by flow cytometry. The cells treated in T25 flasks were collected and fixed in cold 70 % ethanol in PBS overnight at 4°C. After being washed in PBS, the cells were incubated in PBS containing 100 μg/ml RNase and 20 μg/ml propidium iodide at 37°C for 60 min. Thereafter, the DNA content was analysed by the flow cytometer.

Immunocytochemistry

Expression of Ki-67 and phospho-retinoblastoma (pRb) protein at Ser807/811 was determined by immunostaining. The treated cells in T75 flasks were trypsinised, fixed in 10 % buffered formalin solution overnight at 4°C, and then processed for paraffin blocks. Sections with 5 μm thickness were baked at 60°C for 1 h, deparaffinised in xylene, re-hydrated in graded ethanol and distilled water, and subjected to antigen retrieval in Tris–EDTA solution80. The sections were then blocked with 10 % horse serum and incubated with each primary antibody for 20 h at 4°C. The sections were washed with Tris-buffered saline with Tween (TBST) and sequentially labelled with a biotinylated secondary antibody (RA-1000) and Vectastain ABC kit (PK-4000) from Vector Laboratories. The immuno-labelling of indicated antigens was detected with 3,3’-diaminobenzidine (K3468; Dako). The immuno-labelled sections were counterstained with haematoxylin and cover-slipped. The primary antibodies to Ki-67 (RM-9106-S) and pRb at Ser807/811 (9308) were purchased from Labvision and Cell Signalling Technology, respectively.

Quantification of immunostained cells

Immunostained cells were scanned by an automated cellular imaging system equipped with automated cellular
imaging system (ACIS) software (ACIS III; Dako) to acquire digital images. Next, two colour thresholds were selected on the images to distinguish between the positively stained (dark brown) and negatively stained (blue) cells. The cells in ten randomly selected fields were then analysed. The percentage of positive cells of each sample was calculated using the following formula:

\[
\text{positive cells/(positive cells + negative cells)} \times 100
\]

**Immunoblotting**

The cells treated in six-well plates were harvested in lysis buffer (50 mM-Tris-pH 8, 150 mM-NaCl, 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail (11836145001; Roche) and 50 mM-

Table 2. Proliferation of lymph node-metastasised prostate cancer cells (LNCaP), bone metastasised androgen receptor negative prostate cells (PC-3) and bone metastasised androgen receptor positive prostate cells (MDA-PCA-2b) cells measured by Ki-67 staining*

<table>
<thead>
<tr>
<th>Treatment</th>
<th>LNCaP</th>
<th>PC-3</th>
<th>MDA-PCA-2b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>0 % BBP</td>
<td>74.9a</td>
<td>2.9</td>
<td>76.8b</td>
</tr>
<tr>
<td>0.2 % BBP</td>
<td>75.9b</td>
<td>3.0</td>
<td>71.8ab</td>
</tr>
<tr>
<td>0.4 % BBP</td>
<td>59.2b</td>
<td>3.5</td>
<td>63.9b</td>
</tr>
<tr>
<td>0.8 % BBP</td>
<td>24.8b</td>
<td>9.7</td>
<td>24.8b</td>
</tr>
</tbody>
</table>

BBP, blueberry punch.

*a,b,c Mean values within a column with unlike superscript letters were significantly different (P<0.05).

* Average percentage of Ki-67 positive cells with standard deviation from ten randomly selected fields in three independent experiments. Exponentially growing LNCaP, PC-3 or MDA-PCA-2b were treated with the indicated doses of BBP for 72 h. Then the cells were harvested, fixed, embedded in paraffin and immunostained for the expression of Ki-67.

**Statistical analysis**

Statistical comparison was performed using NCSS PASS version 12.0 (NCSS Statistical and Power Analysis Software). The processed data were analysed using one-way ANOVA to determine if a significant change had occurred. Fisher’s least significant difference multiple-comparison test (significance: P<0.05) and Kruskal–Wallis multiple-comparison z-value test (significance: z-value of >1.96) were applied to determine which doses of BBP had a significant effect.

**Results**

**Blueberry punch inhibits the proliferation of prostate cancer cells**

To determine the effect of BBP treatment on cell cycle phase distribution, LNCaP, PC-3 and MDA-PCA-2b cells were treated with BBP (up to 0.8% in corresponding culture medium) for 72 h and then stained with propidium iodide and analysed by flow cytometry. Treatment with 0.2–0.4% BBP blocked cell cycle progression in LNCaP, PC-3 and MDA-PCA-2b cell lines as manifested by an accumulation of cells in the G0/G1 phase and a reduction in the percentage of cells in the S or G2/M phase (Table 1). A further retardation of cell cycle progression was noted with 0.8% BBP treatment. To confirm the reduction of cells in the S phase, DNA synthesis was monitored by Edu incorporation using flow cytometry. Treatment with BBP at the concentration of 0.2–0.4% decreased DNA synthesis (Fig. 1). A further reduction was noted with 0.8% BBP in all three cell lines.

To verify the inhibition of cell cycle progression by BBP, the expression levels of Ki-67, a protein associated with cycling

Table 3. Phosphorylation of retinoblastoma protein in lymph node-metastasised prostate cancer cells (LNCaP), bone metastasised androgen receptor negative prostate cells (PC-3) and bone metastasised androgen receptor positive prostate cells (MDA-PCA-2b) cells

<table>
<thead>
<tr>
<th>Treatment</th>
<th>LNCaP</th>
<th>PC-3</th>
<th>MDA-PCA-2b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>0 % BBP</td>
<td>27.8a</td>
<td>4.9</td>
<td>66.5a</td>
</tr>
<tr>
<td>0.2 % BBP</td>
<td>18.8a</td>
<td>1.7</td>
<td>27.6a</td>
</tr>
<tr>
<td>0.4 % BBP</td>
<td>7.9b</td>
<td>1.5</td>
<td>11.4b</td>
</tr>
<tr>
<td>0.8 % BBP</td>
<td>5.9b</td>
<td>1</td>
<td>7.0b</td>
</tr>
</tbody>
</table>

BBP, blueberry punch.

*a,b,c Mean values within a column with unlike superscript letters were significantly different (P<0.05).

*a Average percentage of phospho-retinoblastoma protein-positive cells with standard deviation from ten randomly selected fields in three independent experiments. Exponentially growing LNCaP, PC-3 or MDA-PCA-2b were treated with the indicated doses of BBP for 72 h. Then the cells were harvested, fixed, embedded in paraffin and immunostained for the phospho-retinoblastoma.
cells, were determined by immunocytochemistry. Consistently, 0.2–0.4% BBP caused a decrease in the percentage of Ki-67 in all three cell lines. There was a further reduction in Ki-67 positivity at 0.8% BBP (Table 2 and Fig. S1 of the supplementary material, available online at http://www.journals.cambridge.org/bjn). Because phosphorylation on pRb has been shown to be correlated with cell cycle progression from the G1 to the S phase\(^{(9)}\), the pRb at Ser\(^{807,811}\) was also determined. BBP treatment reduced phosphorylation on pRb in all treated cell lines to an extent comparable to Ki-67 (Table 3 and Fig. S2 of the supplementary material, available online at http://www.journals.cambridge.org/bjn).

**Modulation of cyclins, cyclin-dependent kinase and cyclin-dependent kinase inhibitor by blueberry punch in prostate cancer cells**

The aforementioned observations suggest that BBP blocks a transition from the G1 to the S phase in treated cells. We therefore determined the levels of cyclin–CDK and their inhibitor P27 involved at G1–S transition in LNCaP and PC-3 cells. BBP treatment decreased the protein levels of cyclin D1/CDK4 and cyclin E/CDK2 in both cell lines (Fig. 2). In LNCaP cells, the observed decreases in the expression of these G1–S transition-regulators are BBP dose-dependent except for CDK2, where a further decrease...
at 0·8 % BBP did not reach the significance levels. In PC-3 cells, the decrease in cyclin and CDK did not reach statistical significance at 0·2–0·4 % BBP, but became significant at 0·8 % BBP. Concurrently, the treatment elevated the protein levels of p27 relative to the control in a dose-dependent manner in LNCaP and although there was a trend of increase in p27 in PC-3, a significant increase was noted only at 0·8 % BBP (Fig. 2).

Suppressive effect of blueberry punch on the expression of MCM7 and cell division cycle 6

The formation of the pre-replication complex is a pre-requisite for DNA replication. MCM7 and CDC6 are the two major components of the pre-replication complex. As BBP inhibited the proliferation in the treated cells, we ascertained whether the MCM7 and CDC6 levels were affected by BBP treatment. As expected, the protein levels of MCM7 and CDC6 in LNCaP and PC-3 cells were reduced by BBP treatment (Fig. 3). In both LNCaP and PC-3 cells, 0·2 or 0·4 % BBP caused a decrease in the MCM7 and CDC6 levels. A further decrease at 0·8 % BBP was noted for the CDC6 levels in LNCaP cells. This finding overall was consistent with the observation that BBP restrained DNA synthesis in prostate cancer cells.

Discussion

In the present study, the anti-proliferative effect of BBP was tested in three prostate cancer cell lines. LNCaP cells were derived from lymph node metastasis and were positive for the androgen receptor (10); while PC-3 cells (10) and MDA-PaCa-2b cells (7) were both derived from bone metastasis, and were negative and positive for the androgen receptor, respectively. The present study demonstrates that food extracts commonly consumed in the Mediterranean and East Asia possess a consistent property of anti-proliferation in all three prostate cancer cell lines with different pathological attributes.

Cell cycle analysis revealed that BBP increased the percentage of cancer cells at the G0/G1 phase and decreased those at the S and G2/M phases, suggesting a blockade of transition from the G1 to the S phase. This is confirmed by a reduction in DNA synthesis by BBP as measured by the incorporation of EdU. A significant decrease in Ki-67 and pRb positive cells after BBP treatment provides further evidence that the proliferation of prostate cancer cells is indeed suppressed. The fact that the treatment reduced the levels of cyclin D1/CDK4 and cyclin E/CDK2, the two complexes essential for regulating the G1→S transition (11–13), and increased the level of p27, a broad inhibitor of CDK complexes (14), provides the mechanistic evidence for the inhibition of cell cycle progression by BBP. The decrease in the percentage of pRb-positive stained nuclei further supports a decrease in CDK activity by BBP treatment, as pRb is a substrate of cyclin D1/CDK4 in the early G1 and cyclin E/CDK2 in the later G1 phase (14).

DNA replication requires a sequential assembly of licensing factors into pre-replication complex at replication origins, and CDC6 and MCM proteins are the major components of the complex (15,16). Down-regulation of licensing factors suppresses the proliferative capacity and keeps cells in the quiescent state (17). As BBP inhibited the proliferation of the cancer cells, we ascertained whether the CDC6 and MCM7 levels were affected by BBP treatment. The finding regarding the reductions in both CDC6 and MCM7 proteins in BBP-treated cells provides further evidence for BBP to restrain DNA synthesis in prostate cancer cells.

As Ki-67 is only expressed in actively cycling cells including G1, S, G2 and mitosis (18), the decrease in Ki-67 positive cells...
after BBP treatment infers an increase in the number of cells at the G0 phase. Thus, we propose that, besides impeding the G1–S transition, BBP may cause slippage of cycling cells to a quiescent state or block quiescent cancer cells re-entering the cell cycle. Further studies to ascertain these possibilities will be interesting and of clinical significance.

The results from the present study support and extend our previous finding that BBP possesses anti-proliferative property under both in vitro and in vivo conditions. However, it is worth noting that LNCaP and PC-3 cell numbers measured by the MTS assay based on mitochondria activity were reduced by 80% at 0.6% BBP in our previous report. The relatively smaller reduction in DNA synthesis compared with the decline in cell numbers suggests that BBP may also be cytotoxic to the cancer cells, although this cytotoxic effect is expected to be less than the cytostatic effect.

Considering that alterations in multiple pathways are required for cancer progression, chemoprevention strategy needs to target multiple pathways accordingly. We have shown recently that BBP simultaneously affects the AKT, androgen receptor and cytosolic phospholipase A2 signalling pathways that are essential to the proliferation of prostate cancer cells. In the present study, we have provided mechanistic evidence that BBP modulates the levels of key regulators that are involved in the cell cycle progression and the formation of pre-replication complex. Normalisation of aberrant expression of these key regulatory proteins is expected to lead to an inhibition of cancer cell proliferation. Thus, a randomised, double-blind, placebo-controlled clinical trial of BBP should be considered for patients with low-grade and early prostate cancer who are currently under active surveillance.

Acknowledgements

The present work was supported by Sydney Medical School Foundation (Q. D.) and Dr Red Nutraceuticals (Q. D.). M. Y., C. X., M. C., S. H., B. D. H. and P. S. have no conflicts of interest. Q. D. holds research funds from Dr Red Nutraceuticals and G. J. is an employee of Dr Red Nutraceuticals. M. Y., C. X., M. C., S. H. and G. J. conducted the research; B. D. H. and P. S. analysed the data; M. Y. and Q. D. designed the experiments; and M. Y., C. X., M. C., S. H. and Q. D. prepared the manuscript. The authors thank Masuo Yamaoka (Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company) for the MDA-PCa-2b cell line.

References